The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.
Open accessAbstract
Advanced glycosylation end products (AGEs) have been implicated in many of the complications of diabetes and normal aging. Markedly elevated vascular tissue and circulating AGEs were linked recently to the accelerated vasculopathy of end-stage diabetic renal disease. To determine the pathogenic role of AGEs in vivo, AGE-modified albumin was administered to healthy nondiabetic rats and rabbits alone or in combination with the AGE-crosslink inhibitor aminoguanidine. Within 2-4 weeks of AGE treatment, the AGE content of aortic tissue samples rose to six times the amount found in controls (P < 0.001). Cotreatment with aminoguanidine limited tissue AGE accumulation to levels two times that of control. AGE administration was associated with a significant increase in vascular permeability, as assessed by 125I label tracer methods. This alteration was absent in animals that received aminoguanidine in addition to AGE. Significant mononuclear cell migratory activity was observed in subendothelial and periarteriolar spaces in various tissues from AGE-treated rats compared to normal cellularity noted in tissues from animals treated with aminoguanidine. Blood pressure studies of AGE-treated rats and rabbits revealed markedly defective vasodilatory responses to acetylcholine and nitroglycerin compared to controls (P < 0.001), consistent with marked NO. inactivation; aminoguanidine treatment significantly prevented this defect. These in vivo data demonstrate directly that AGEs, independent of metabolic or genetic factors, can induce complex vascular alterations resembling those seen in diabetes or aging. AGE administration represents an animal model system for the study of diabetic and aging complications as well as for assessing the efficacy of newly emerging therapies aimed at inhibiting advanced glycosylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Atherosclerosis — An Update
Ross, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140806 · Cited by 4,877
Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
Flier, J. S., Underhill, L. H., Brownlee, M., Cerami, A., & Vlassara, H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805193182007 · Cited by 2,511
Self-citationBucala, R., Tracey, K. J., & Cerami, A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115014 · Cited by 1,165
Self-citationAminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking
Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., & Cerami, A. (1986) · Science · doi:10.1126/science.3487117 · Cited by 1,146
Self-citationAdvanced Glycosylation End Products in Patients with Diabetic Nephropathy
Makita, Z., Radoff, S., Rayfield, E. J., Yang, Z., Skolnik, E., Delaney, V., Friedman, E. A., Cerami, A., & Vlassara, H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109193251202 · Cited by 918
Self-citationBarger, A. C., Beeuwkes, R., Lainey, L. L., & Silverman, K. J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401193100307 · Cited by 849
Accelerated age-related browning of human collagen in diabetes mellitus.
Monnier, V. M., Kohn, R. R., & Cerami, A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.2.583 · Cited by 671
Self-citationCachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue Remodeling
Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A., & Pasagian, A. (1988) · Science · doi:10.1126/science.3259727 · Cited by 597
Self-citationAminoguanidine treatment inhibits the development of experimental diabetic retinopathy.
Hammes, H. P., Martin, S., Federlin, K., Geisen, K., & Brownlee, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11555 · Cited by 524
Immunochemical detection of advanced glycosylation end products in vivo.
Makita, Z., Vlassara, H., Cerami, A., & Bucala, R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42741-x · Cited by 491
Self-citation
Cited by
Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose
Thornalley, P. J., LANGBORG, A., & Minhas, H. S. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440109 · Cited by 1,243
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
Williams, S. B., Cusco, J. A., Roddy, M.-A., Johnstone, M. T., & Creager, M. A. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00522-6 · Cited by 1,014
BASTA, G. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.05.001 · Cited by 999
Wang (2012) · doi:10.1161/circresaha.111.261388 · Cited by 957
Ting, H. H., Timimi, F. K., Boles, K. S., Creager, S. J., Ganz, P., & Creager, M. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118394 · Cited by 871
Koschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., & Vlassara, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6474 · Cited by 792
Self-citationDiabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Self-citationChaudhuri, J., Bains, Y., Guha, S., Kahn, A., Hall, D., Bose, N., Gugliucci, A., & Kapahi, P. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.014 · Cited by 669
Aronson, D. (2003) · Journal of Hypertension · doi:10.1097/00004872-200301000-00002 · Cited by 651
Type 2 diabetes mellitus, cognitive impairment and dementia
Stewart, R., & Liolitsa, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00027.x · Cited by 562
Bierhaus, A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00233-2 · Cited by 555
Tobacco smoke is a source of toxic reactive glycation products
Cerami, C., Founds, H., Nicholl, I., Mitsuhashi, T., Giordano, D., Vanpatten, S., Lee, A., Al-Abed, Y., Vlassara, H., Bucala, R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13915 · Cited by 549
Self-citationHow hyperglycemia promotes atherosclerosis: molecular mechanisms
Aronson, D., & Rayfield, E. J. (2002) · Cardiovascular Diabetology · doi:10.1186/1475-2840-1-1 · Cited by 504
Does accumulation of advanced glycation end products contribute to the aging phenotype?
Semba, R. D., Nicklett, E. J., & Ferrucci, L. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq074 · Cited by 490
Gerhard, M., Roddy, M.-A., Creager, S. J., & Creager, M. A. (1996) · Hypertension · doi:10.1161/01.hyp.27.4.849 · Cited by 470
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
Vasan, S., Zhang, X., Zhang, X., Kapurniotu, A., Bernhagen, J., Teichberg, S., Basgen, J., Wagle, D., Shih, D., Terlecky, I., et al. (1996) · Nature · doi:10.1038/382275a0 · Cited by 466
Self-citationAdvanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li, Y. M., & Steffes, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11704 · Cited by 462
Self-citationEndothelial dysfunction and pathogenesis of diabetic angiopathy
Stehouwer, C. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00272-6 · Cited by 441
Morigi, M., Angioletti, S., Imberti, B., Donadelli, R., Micheletti, G., Figliuzzi, M., Remuzzi, A., Zoja, C., & Remuzzi, G. (1998) · Journal of Clinical Investigation · doi:10.1172/jci656 · Cited by 438
Advanced glycation end products increase retinal vascular endothelial growth factor expression.
Lu, M., Kuroki, M., Amano, S., Tolentino, M., Keough, K., Kim, I., Bucala, R., & Adamis, A. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1277 · Cited by 423
Self-citationHyperglycemia and Glycation in Diabetic Complications
Negre-Salvayre, A., Salvayre, R., Augé, N., Pamplona, R., & Portero-Otín, M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2484 · Cited by 421
Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
Makita, Z., Bucala, R., Rayfield, E. J., Fuh, H., Manogue, K. R., Cerami, A., Viassara, H., Friedman, E. A., Kaufman, A. M., Korbet, S. M., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92935-1 · Cited by 373
Self-citationAdvanced glycation endproducts: what is their relevance to diabetic complications?
Ahmed, N., & Thornalley, P. J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00595.x · Cited by 371
Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms
Stirban, A., Gawlowski, T., & Roden, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.11.006 · Cited by 361
Schrijvers, B. F., De Vriese, A. S., & Flyvbjerg, A. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0018 · Cited by 353
Scheijen, J. L. J. M., Clevers, E., Engelen, L., Dagnelie, P. C., Brouns, F., Stehouwer, C. D. A., & Schalkwijk, C. G. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2015.06.049 · Cited by 343
The role of oxidative stress and NF‐κB activation in late diabetic complications
Mohamed, A. K., Bierhaus, A., Schiekofer, S., Tritschler, H., Ziegler, R., & Nawroth, P. P. (1999) · BioFactors · doi:10.1002/biof.5520100211 · Cited by 339
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Self-citationThornalley, P. J. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00157-9 · Cited by 308
Advanced glycation: an important pathological event in diabetic and age related ocular disease
STITT, A. W. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.6.746 · Cited by 306
Smoking Is Related to Albuminuria and Abnormal Renal Function in Nondiabetic Persons
Pinto-Sietsma, S.-J., Mulder, J., Janssen, W. M. T., Hillege, H. L., de Zeeuw, D., & de Jong, P. E. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-8-200010170-00008 · Cited by 297
Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.
Yang, C. W., Vlassara, H., Peten, E. P., He, C. J., Striker, G. E., & Striker, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9436 · Cited by 294
Self-citationGap Junctions in the Control of Vascular Function
Figueroa, X. F., & Duling, B. R. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2117 · Cited by 294
Advanced glycation end products: A nephrologist's perspective
Raj, D. S. C., Choudhury, D., Welbourne, T. C., & Levi, M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70189-2 · Cited by 290
In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs)
Booth, A. A., Khalifah, R. G., Todd, P., & Hudson, B. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5430 · Cited by 286
Glycation Induces Formation of Amyloid Cross-β Structure in Albumin
Bouma, B., Kroon-Batenburg, L. M. J., Wu, Y.-P., Brünjes, B., Posthuma, G., Kranenburg, O., de Groot, P. G., Voest, E. E., & Gebbink, M. F. B. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303925200 · Cited by 286
Quehenberger, P., Bierhaus, A., Fasching, P., Muellner, C., Klevesath, M., Hong, M., Stier, G., Sattler, M., Schleicher, E., Speiser, W., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.9.1561 · Cited by 283
Shipanova, I. N., Glomb, M. A., & Nagaraj, R. H. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0195 · Cited by 279
AGE restriction in diabetes mellitus: a paradigm shift
Vlassara, H., & Striker, G. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.74 · Cited by 277
“AGEs and diabetes mellitus: a paradigm shift Animal studies The unique pathogenic role of AGEs as environmental toxins has been amply supported by studies showing that the parenteral or oral administration of chemically designed AGEs leads to a cycle of increased cell and tissue AGEs, oxidative stress and inflammation…”
Self-citationDiabetes mellitus and dementia
Pasquier, F., Boulogne, A., Leys, D., & Fontaine, P. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70298-7 · Cited by 276
Mechanisms of diabetic vasculopathy: an overview
Cooper, M. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01323-6 · Cited by 267
Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
Flyvbjerg, A., Denner, L., Schrijvers, B. F., Tilton, R. G., Mogensen, T. H., Paludan, S. R., & Rasch, R. (2004) · Diabetes · doi:10.2337/diabetes.53.1.166 · Cited by 187
Menini, S., Iacobini, C., Ricci, C., Oddi, G., Pesce, C., Pugliese, F., Block, K., Abboud, H. E., Giorgio, M., Migliaccio, E., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0728-7 · Cited by 64
Metadata
- Authors
- Vlassara, H., Fuh, H., Makita, Z., Krungkrai, S., Cerami, A., & Bucala, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-12-15
- Volume
- 89
- Issue
- 24
- Pages
- 12043-12047
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2060895623
- Cited by
- 377
- References
- 23
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.